Home » Newsletters » BioWorld

BioWorld

March 4, 1997

View Archived Issues

Cor Therapeutics' Stock Plummets Monday Following Friday's Panel Rejection

Other News to Note

FDA Proposes New Plan To Regulate Cell, Tissue Products

Centocor, GenPharm $57M Deal Targets Development Of Human Antibodies

Homosexual Man Lacking CCR5 Gene Tests Positive, With Declining CD4 Count

IDEC, Genentech Seek FDA Approval For Cancer Monoclonal Antibody

Bristol-Myers Becomes Incyte's 14th Data Base Subscriber

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.